Arecor Partners to Innovate Peptide Therapy Formulation

Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an update.

Arecor Therapeutics plc has announced a collaboration with a clinical-stage biopharmaceutical company to develop a novel formulation of peptide therapy using its Arestat™ technology platform. This partnership, which includes funding for development and an option for the partner to license the new formulation, underscores Arecor’s leadership in the peptide therapeutics market, a sector projected to exceed $100 billion by 2034. The collaboration aims to leverage Arecor’s expertise in creating advanced peptide formulations, addressing unmet patient needs in a rapidly growing market driven by the rise of endocrine and metabolic diseases.

More about Arecor Therapeutics PLC

Arecor Therapeutics plc is a global biopharmaceutical company focused on transforming patient care by enhancing existing therapeutic products. Utilizing its proprietary Arestat™ technology platform, Arecor develops an internal portfolio of products targeting diabetes and other indications, while collaborating with leading pharmaceutical and biotechnology companies to deliver innovative therapeutic solutions.

YTD Price Performance: -31.29%

Average Trading Volume: 12,353

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £19.07M

See more data about AREC stock on TipRanks’ Stock Analysis page.